HSP90 Expression: A New Predictive Factor for BCG Response in Stage Ta-T1 Grade 3 Bladder Tumours

European Urology

Volumn 51, Issue 1, 2007, Pages 161-167

  Lebret, Thierry ^a,b   Watson, R William G ^b   Molinié, Vincent ^a   Poulain, Jean Eudes ^a   O'Neill, Amanda ^b   Fitzpatrick, John M ^b   Botto, Henry ^a  

^a FOCH HOSPITAL   (France)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Apoptosis; Bladder carcinoma; Heat shock protein; Neoplasm; Superficial bladder tumour

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; HEAT SHOCK PROTEIN 90;

ARTICLE; BLADDER CANCER; BLADDER TUMOR; CANCER ADJUVANT THERAPY; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTECTOMY; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 33751398435     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.06.006     Document Type: Article

References (33)

1. Herr H.W., Wartinger D.D., Fair W.R., and Oettgen H.F. Bacillus Calmette-Guérin therapy for superficial bladder cancer: a 10-year follow-up. J Urol 147 (1992) 1020-1024
2. Shahin O., Thalmann G.N., Rentsch C., Mazzucchelli L., and Studer U.E. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guérin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169 (2003) 96-100
3. Lebret T., Bohin D., Kassardjian Z., et al. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guérin instillations. J Urol 163 (2000) 63-67
4. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
5. Lebret T., Watson R.W., Molinie V., et al. Heat shock proteins HSP27, HSP60, HSP70 and HSP90 expression in bladder carcinoma. Cancer 98 (2003) 970-977
6. Welch W.J. Mammalian stress response: cell physiology, structure/function of stress proteins and implications for medicine and disease. Physiol Rev 72 (1992) 1063-1081
7. Sireci G., Dieli F., and Salerno A. T cells recognize an immunodominant epitope of heat shock protein 65 in Kawasaki disease. Mol Med 6 (2000) 581-590
8. Kaufmann S.H. Heat shock proteins and the immune response. Immunol Today 11 (1990) 129-136
9. Lebret T., Watson R.W., and Fitzpatrick J.M. Heat shock proteins: their role in urological tumors. J Urol 169 (2003) 338-346
10. Bostwick D.G., and Mikuz G. Urothelial papillary (exophytic) neoplasm. Virchows Arch 441 (2002) 109-161
11. In: Sohbin L.H., and Wittekind C. (Eds). UICC: TNM Classification of Malignant Tumors. 5th ed. (1997), John Wiley, New York
12. Vanmuylder N., Evrard L., Daelemans P., Van Reck J., and Dourov N. Immunohistochemical expression of heat shock proteins HSP27, HSP70, HSP90 and HSP110 in salivary gland tumors: a study of 50 cases. Ann Pathol 20 (2000) 190-195
13. Fitzpatrick J.M., West A.B., Butler M.R., Lane V., and O'Flynn J.D. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol 135 (1986) 920-922
14. Lebret T., Gaudez F., Hervé J.M., Barré P., Lugagne P.M., and Botto H. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Eur Urol 34 (1998) 67-72
15. Herr H.W. Natural history of superficial bladder tumors: 10 to 20-year follow-up of treated patients. World J Urol 15 (1997) 84-88
16. Brandau S., and Bohle A. Bladder cancer. Molecular and genetic basis of carcinogenesis. Eur Urol 39 (2001) 491-497
17. Zlotta A.R., Drowart A., Van Vooren J.P., et al. Superficial bladder tumors and increased reactivity against mycobacterial antigens before bacillus Calmette-Guerin therapy. J Urol 159 (1998) 1885-1891
18. Srivastava P.K. Heat shock proteins in immune response to cancer: the fourth paradigm. Experientia 50 (1994) 1054-1060
19. Cardillo M.R., Sale P., and Di Silverio F. Heat shock protein-90, IL-6, IL-10 in bladder cancer. Anticancer Res 20 (2000) 4579-4584
20. Harada M., Kimura G., and Nomoto K. Heat-shock proteins and the antitumor T cell response. Biotherapy 10 (1998) 229-235
21. Craig E.A. Chaperones: helpers along the pathways to protein folding. Science 260 (1993) 1902-1903
22. Welch W.J. Mammalian stress response: cell physiology, structure/function of stress proteins and application for medicine and disease. Physiol Rev 72 (1992) 1063-1081
23. Trieb K., Lang S., and Kotz R. Heat-shock protein 72 in human osteosarcoma: T-lymphocyte reactivity and cytotoxicity. Pediatr Hematol Oncol 17 (2000) 355-364
24. Hara I., Sato N., Miyake H., Muramaki M., Hikosaka S., and Kamidono S. Introduction of 65 kDa antigen of Mycobacterium tuberculosis to cancer cells enhances anti-tumor effect of BCG therapy. Microbiol Immunol 48 (2004) 289-295
25. Zlotta A.R., Drowart A., Huygen K., et al. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette-Guérin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol 109 (1997) 157-165
26. Richards E.H., Hickman J.A., and Master J.R. Heat shock protein expression in testis and bladder cancer cell lines exhibiting differential sensitivity to heat. Br Cancer 72 (1995) 620-626
27. Wells A.D., and Malkkovksy M. Heat shock proteins, tumor immunogenicity and antigen presentation: an integrated view. Immunol Today 21 (2000) 129-132
28. Feng H., Zeng Y., Whitesell L., and Katsanis E. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood 97 (2001) 3505-3512
29. Shahin O., Thalmann G.N., Rentsch C., Mazzucchelli L., and Studer U.E. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169 (2003) 96-100
30. Lebret T., Bohin D., Kassardjian Z., Herve J.M., Molinie V., Barre P., et al. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol 163 (2000) 63-67
31. Welch W.J. Mammalian stress response: cell physiology, structure/function of stress proteins, and implications for medicine and disease. Physiol Rev 72 (1992) 1063-1081
32. Keppler BR, Grady AT, Jarstfer MB. The biochemical role of the heat shock protein 90 chaperone complex in establishing human telomerase activity. J Biol Chem 2006; [Epub ahead of print].
33. Li Z., Menoret A., and Srivastava P. Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol 14 (2002) 45-51